Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

LRRK2 Antikörper (AA 930-961)

Der Kaninchen Polyklonal Anti-LRRK2-Antikörper wurde für WB und IF validiert. Er ist geeignet, LRRK2 in Proben von Human und Maus zu detektieren. Es sind 2+ Publikationen verfügbar.
Produktnummer ABIN391148

Kurzübersicht für LRRK2 Antikörper (AA 930-961) (ABIN391148)

Target

Alle LRRK2 Antikörper anzeigen
LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Reaktivität

Human, Maus

Wirt

  • 7
  • 3
Kaninchen

Klonalität

  • 7
  • 3
Polyklonal

Konjugat

  • 10
Dieser LRRK2 Antikörper ist unkonjugiert

Applikation

  • 9
  • 5
  • 3
  • 2
  • 1
  • 1
Western Blotting (WB), Immunofluorescence (IF)

Klon

RB07209
  • Bindungsspezifität

    • 5
    • 2
    • 2
    • 1
    • 1
    AA 930-961

    Aufreinigung

    This antibody is purified through a protein A column, followed by peptide affinity purification.

    Immunogen

    This PARK8(LRRK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 930-961 amino acids from human PARK8(LRRK2).

    Isotyp

    Ig Fraction
  • Applikationshinweise

    IF: 1:10~50. WB: 1:1000. WB: 1:1000

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Liquid

    Buffer

    Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    4 °C,-20 °C

    Informationen zur Lagerung

    Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

    Haltbarkeit

    6 months
  • Huang, Song, Murphy, Holton, Lashley, Revesz, Gai, Halliday: "LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions." in: Acta neuropathologica, Vol. 116, Issue 6, pp. 639-46, (2009) (PubMed).

    Biskup, Moore, Rea, Lorenz-Deperieux, Coombes, Dawson, Dawson, West: "Dynamic and redundant regulation of LRRK2 and LRRK1 expression." in: BMC neuroscience, Vol. 8, pp. 102, (2008) (PubMed).

  • Target

    LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

    Andere Bezeichnung

    PARK8 (LRRK2)

    Hintergrund

    Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. LRRK2 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

    Molekulargewicht

    286103

    Gen-ID

    120892

    NCBI Accession

    NP_940980

    UniProt

    Q5S007

    Pathways

    Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development
Sie sind hier:
Chat with us!